公开(公告)号：EP2316430A1

公开(公告)日：2011-05-04

申请号：EP10182198.1

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd W ,  Robinson, Joseph R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract translation: 本发明涉及包含富马酸酯作为活性物质的控释药物组合物。 该组合物适合用于治疗例如儿童。 牛皮癣或其他过度增生，炎性或自身免疫性疾病，并且被设计为以受控的方式释放富马酸酯，使得可以避免在口服给药时胃肠道内的活性物质的局部高浓度，从而能够减少胃 - 肠道相关副作用。

公开(公告)号：EP3295936A1

公开(公告)日：2018-03-21

申请号：EP17170304.4

申请日：2010-01-08

Applicant: Forward Pharma A/S

Inventor： NILSSON, Henrik ,  RUPP, Roland

IPC: A61K9/28 ,  A61K31/215 ,  A61P17/06 ,  A61K9/20 ,  A61K31/225

CPC classification number: A61K9/28 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/215 ,  A61K31/225

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract translation: 包含侵蚀基质的药物制剂，所述侵蚀基质包含一种或多种富马酸酯以及一种或多种速率控制剂，其中所述侵蚀基质的侵蚀允许所述富马酸酯的受控释放。

公开(公告)号：EP1799196B1

公开(公告)日：2016-06-22

申请号：EP05789026.1

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： NILSSON, Henrik ,  SCHÖNHARTING, Florian ,  MÜLLER, Bernd, W. ,  ROBINSON, Joseph, R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP2879672A1

公开(公告)日：2015-06-10

申请号：EP13745073.0

申请日：2013-08-02

Applicant: Forward Pharma A/S

Inventor： TERWEY, Theis ,  RUPP, Ronald ,  ANDERSEN, Peder M.

IPC: A61K31/215 ,  A61K31/275 ,  A61K9/00 ,  A61P29/00 ,  A61K31/137 ,  A61K31/47

CPC classification number: A61K31/225 ,  A61K9/209 ,  A61K9/28 ,  A61K31/137 ,  A61K31/215 ,  A61K31/275 ,  A61K31/277 ,  A61K31/47 ,  A61K31/4704 ,  A61K2300/00

Abstract: The present invention relates to a method of treating MS in a human patient in need of such treatment and comprises administering to said patient a combination therapy in a single oral dosage form (e.g. a tablet or capsule) of dimethylfumarate and one agent selected from teriflunomide (or its prodrug leflunomide), fingolimod and laquinimod. This combination is more effective than the single agents alone and/or has reduced side effects and better tolerability than the single agents alone and/or can be given in a reduced frequency. Moreover, the present invention is directed to a pharmaceutical composition suitable for the oral treatment of multiple sclerosis consisting of dimethylfumarate and one agent selected from teriflunomide, fingolimod and laquinimod as active ingredients and one or more pharmaceutically acceptable excipients.

Abstract translation: 本发明涉及在需要这种治疗的人类患者中治疗MS的方法，并且包括向所述患者施用单独的口服剂型（例如片剂或胶囊）的富马酸二甲酯和一种选自特菲里铵的药剂（ 或其前药来氟米特），芬戈莫德和拉喹莫德。 这种组合比单独的单一试剂更有效，和/或具有比单独的单一试剂降低的副作用和更好的耐受性和/或可以以降低的频率给予。 此外，本发明涉及一种适用于口服治疗由富马酸二甲酯和一种选自特芬龙胺，芬戈莫德和拉喹莫德作为活性成分的药剂和一种或多种药学上可接受的赋形剂的多发性硬化症的药物组合物。

公开(公告)号：EP2801354A1

公开(公告)日：2014-11-12

申请号：EP14172390.8

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd, W. ,  Robinson, Joseph, R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising a fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：EP2965751A1

公开(公告)日：2016-01-13

申请号：EP15166243.4

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd, W. ,  Robinson, Joseph, R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising a fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract translation: 本发明涉及包含作为活性物质的富马酸酯的控释药物组合物。 该组合物适合用于治疗例如儿童。 牛皮癣或其他过度增生，炎症或自身免疫性疾病，并被指定以受控的方式释放富马酸酯，使得可以避免在口服给药时胃肠道内的活性物质的局部高浓度，从而能够减少胃 - 肠道相关副作用。

公开(公告)号：EP2792349A2

公开(公告)日：2014-10-22

申请号：EP14172396.5

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd, W. ,  Robinson, Joseph, R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising a fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

公开(公告)号：EP2564839A2

公开(公告)日：2013-03-06

申请号：EP12193798.1

申请日：2010-01-08

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Rupp, Roland

IPC: A61K9/28 ,  A61K31/215 ,  A61P17/06 ,  A61K9/20 ,  A61K31/225

CPC classification number: A61K9/28 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886 ,  A61K31/215 ,  A61K31/225

Abstract: A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).

Abstract translation: 包含含有一种或多种富马酸酯的腐蚀基质以及一种或多种速率控制剂的药物制剂，其中所述侵蚀基质的侵蚀允许所述富马酸酯的受控释放。

公开(公告)号：EP2316430B1

公开(公告)日：2012-06-06

申请号：EP10182198.1

申请日：2005-10-07

Applicant: Forward Pharma A/S

Inventor： Nilsson, Henrik ,  Schönharting, Florian ,  Müller, Bernd W ,  Robinson, Joseph R.

IPC: A61K9/20

CPC classification number: A61K31/225 ,  A61K9/0053 ,  A61K9/14 ,  A61K9/167 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/28 ,  A61K9/2846 ,  A61K9/48 ,  A61K9/4808 ,  A61K9/4891 ,  A61K9/50 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/215 ,  A61K31/22 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract translation: 本发明涉及包含富马酸酯作为活性物质的控释药物组合物。 该组合物适用于治疗例如， 牛皮癣或其它过度增殖性，炎症性或自身免疫性疾病，并设计成以受控方式释放延胡索酸酯，从而避免口服给药时局部高浓度的胃肠道内的活性物质，从而能够减少胃 肠道相关的副作用。